DOI QR코드

DOI QR Code

Clinical Predictive Value of Serum Angiogenic Factor in Patients with Osteosarcoma

  • Chen, Zhe (Department of Orthopaedics, The Second Affiliated Hospital, Medical College, Zhejiang University) ;
  • Chen, Qi-Xin (Department of Orthopaedics, The Second Affiliated Hospital, Medical College, Zhejiang University) ;
  • Hou, Zhao-Yang (Department of Orthopaedics, The Second Affiliated Hospital of Zhejiang Chinese Medical University) ;
  • Hu, Jiong (Department of Orthopaedics, The Second Affiliated Hospital of Zhejiang Chinese Medical University) ;
  • Cao, Yan-Guang (Department of Orthopaedics, The Second Affiliated Hospital of Zhejiang Chinese Medical University)
  • Published : 2012.09.30

Abstract

Objective: To explore serum angiogenic factor expression in patients with osteosarcoma and its relationship with metastasis. Methods: Immunohistochemistry was used to test the expression of CD34 and FVIII-Rag in osteosarcoma tissues of 36 patients (osteosarcoma group) and microvessel density (MVD) was also recorded. In addition, ELISA was used to test the level of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), transforming growth factor-${\beta}1$ (TGF-${\beta}1$) and endostatin (ES) in the osteosarcoma group and in a control group. Results: VEGF and ES level were significantly higher than in the control group before operation (P<0.01), VEGF, bFGF and TGF-${\beta}1$ correlating with the ES level (P<0.01). Serum VEGF and ES levels of osteosarcoma patients before surgery were closely related to relapse and metastasis; moreover, serum VEGF increased with MVD (P<0.01). Postoperative VEGF and ES levels were lower than the preoperation values (P<0.01); ES level in relapse group was significantly higher than that of the non-relapse group (P<0.01). Conclusion: Preoperative serum VEGF and postoperative ES levels have great predictive value with regard to relapse of osteosarcoma patients.

References

  1. Balu S, Pirtea L, Gaje P, et al (2012). The immunohistochemical expression of endocrine gland-derived-VEGF (EG-VEGF) as a prognostic marker in ovarian cancer. Rom J Morphol Embryol, 53, 479-83.
  2. Dirkx AE, oude Egbrink MG, Castermans K, et al (2006). Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J, 20, 621-30. https://doi.org/10.1096/fj.05-4493com
  3. Gao LL, Huang XE, Zhang Q, et al (2011). A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
  4. Hlobilkova A, Ehrmann J, Knizetova P, et al (2009). Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression. Neoplasma, 56, 284-90. https://doi.org/10.4149/neo_2009_04_284
  5. Kasuya K, Nagakawa Y, Suzuki M, et al (2011). Anti-vascular endothelial growth factor antibody single therapy for pancreatic neuroendocrine carcinoma exhibits a marked tumor growth-inhibitory effect. Exp Ther Med, 2, 1047-52.
  6. Kim HS, Lim SJ, Park YK (2009). Anti-angiogenic factor endostatin in osteosarcoma. APMIS, 117, 716-23. https://doi.org/10.1111/j.1600-0463.2009.02524.x
  7. Lee JA, Ko Y, Kim DH, et al (2012). Epidermal growth factor receptor: is it a feasible target for the treatment of osteosarcoma? Cancer Res Treat, 44, 202-9. https://doi.org/10.4143/crt.2012.44.3.202
  8. Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of OxyContin(R) administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
  9. Li CG, Huang XE, Li Y, et al (2011). Phase II Trial of Irinotecan plus Nedaplatin (INP) in Treating Patients with Extensive Stage Small Cell Lung Cancer. Asian Pacific J Cancer Prev, 12, 487-90.
  10. Limmahakhun S, Pothacharoen P, Theera-Umpon N, et al(2011). Relationships between serum biomarker levels and clinical presentation of human osteosarcomas. Asian Pac J Cancer Prev, 12, 1717-22.
  11. Malamitsi-Puchner A, Boutsikou T, Economou E, et al (2005). The role of the anti-angiogenic factor endostatin in intrauterine growth restriction. J Soc Gynecol Investig, 12, 195-7. https://doi.org/10.1016/j.jsgi.2005.01.006
  12. Nataraj NB, Salimath BP (2012). Crosstalk between VEGF and novel angiogenic protein regulates tumor angiogenesis and contributes to aggressiveness of breast carcinoma. Cell Signal, 25, 277-94.
  13. Oda Y, Yamamoto H, Tamiya S, et al (2006). CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol, 19, 738-45. https://doi.org/10.1038/modpathol.3800587
  14. Sunshine SB, Dallabrida SM, Durand E, et al (2012). Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition. Proc Natl Acad Sci U S A, 109, 11306-11. https://doi.org/10.1073/pnas.1203275109
  15. Tan H, Mu G, Zhu W, et al (2011). Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium derived factor make low molecular weight heparin-endostatin and polyethylene glycol-endostatin potential candidates for anti-angiogenesis drug. Biol Pharm Bull, 34, 545. https://doi.org/10.1248/bpb.34.545
  16. Tsubaki M, Yamazoe Y, Yanae M, et al (2011). Blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathways by statins reduces the expression of bFGF, HGF, and TGF-${\beta}$ as angiogenic factors in mouse osteosarcoma. Cytokine, 54, 100-7. https://doi.org/10.1016/j.cyto.2011.01.005
  17. Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
  18. Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar(R) combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
  19. Yang J, McNeish B, Butterfield C, et al (2012). Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB J, Epub ahead of print.
  20. Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
  21. Zhang G, Li M, Jin J, Bai Y (2011). Knockdown of S100A4 decreases tumorigenesis and metastasis in osteosarcoma cells by repression of matrix metalloproteinase-9. Asian Pac J Cancer Prev, 12, 2075-80.
  22. Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a metaanalysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
  23. Zheng MJ (2009). Endostatin derivative angiogenesis inhibitors. Chin Med J, 122, 1947-51.

Cited by

  1. Benzochloroporphyrin Derivative Induced Cytotoxicity and Inhibition of Tumor Recurrence During Photodynamic Therapy for Osteosarcoma vol.14, pp.5, 2013, https://doi.org/10.7314/APJCP.2013.14.5.3351
  2. A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma vol.34, pp.3, 2013, https://doi.org/10.1007/s13277-013-0733-z
  3. Apurinic/apyrimidinic endonuclease 1 regulates angiogenesis in a transforming growth factor β-dependent manner in human osteosarcoma vol.106, pp.10, 2015, https://doi.org/10.1111/cas.12763
  4. Improved Survival in Osteosarcoma Patients with Atypical Low Vascularization vol.22, pp.2, 2015, https://doi.org/10.1245/s10434-014-4001-2
  5. High-level expression of periostin is significantly correlated with tumour angiogenesis and poor prognosis in osteosarcoma vol.97, pp.1, 2016, https://doi.org/10.1111/iep.12171
  6. Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study vol.17, pp.1, 2017, https://doi.org/10.1186/s12885-017-3409-z
  7. Blood-borne biomarkers of osteosarcoma: A systematic review pp.15455009, 2018, https://doi.org/10.1002/pbc.27462